FDA approves isatuximab-irfc, in combination with pomalidomide and dexamethasone for relapsed refractory multiple myeloma

The decision was made after a pivotal trial found it significantly reduced the risk of disease progression or death by 40% vs pomalidomide & dexamethasone. It is approved only in patients who have received two prior therapies including lenalidomide and a proteasome inhibitor.